1. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Issue 5 (9th April 2021) Authors: Kaul, Martin; End, Peter; Cabanski, Maciej; Schuhler, Carole; Jakab, Annamaria; Kistowska, Magdalena; Kinhikar, Arvind; Maiolica, Alessio; Sinn, Angela; Fuhr, Rainard; Cenni, Bruno Journal: Clinical and translational science Issue: Volume 14:Issue 5(2021) Page Start: 1756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. Issue 3 (4th September 2021) Authors: Sinn, Angela; García‐Alvarado, Fernanda; Gonzalez, Veronica; Huerga, Camino; Bullo, Felicitas Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 3(2022) Page Start: 1063 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗